Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT05669820
Recruiting Phase 2/3

Antisecretory Factor Glioblastoma Phase 2

NCT05669820 · tracked via the Priya Life Science Sweden tracker
Sponsor
Peter Siesjö
Phase
Phase 2/3
Started
2024-01-15
Last updated
2026-01-09

Condition(s) studied

Glioblastoma

Investigational drug(s) / intervention(s)

SalovumPlacebo egg yolk powder

Salovum: Salovum is an eggyolkpowder derived from hens fed with SPC (specially processed cereals) and contains increased amounts of the endogenous protein antisecretory factor.

Placebo egg yolk powder: Egg yolk powder derived from hen fed with normal feed.

Study summary

This is a randomised, double blinded and multiple center , Phase 2 study in patients with newly diagnosed glioblastoma. Participants will receive an egg powder enriched for antisecretory factor (AF), Salovum, or a placebo egg powder daily from 2 days before concomitant radio-chemo therapy or chemotherapy until 14 days after finalisation plus during adjuvant chemotherapy.The primary aims of are overall survival at 6 and 12 months after diagnosis

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: 1. Pathology verified glioblastoma or astrocytoma grade 4 2. Age 18-75 years 3. Surgical treatment-resection. 4. Scheduled concomitant radiochemotherapy, or only chemotherapy. 5. Informed consent Exclusion Criteria: 1. No informed consent 2. Egg yolk allergy 3. Only surgical biopsy 4. Only radiotherapy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Skåne University Hospital Lund Sweden Recruiting

More Peter Siesjö trials in Sweden

Antisecretory Factor In Severe Traumatic Brain Injury Recruiting
Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma Recruiting
Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema Recruiting

Other trials for the same condition

Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma Recruiting
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM Recruiting
Surgery for Recurrent Glioblastoma Recruiting
Supramarginal Resection in Glioblastoma Active, not recruiting
Impact of Salovum® and SPC® Flakes on Brain Tumor Induced Edema Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05669820 on ClinicalTrials.gov ↗ ← All trials in Sweden